MannKind Scores Sanofi As A Partner For Afrezza – But At A Price
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi appears to be an ideal match to sell MannKind’s inhaled insulin Afrezza, but the terms of the exclusive worldwide licensing agreement for the product reflect its high-risk nature.